Cargando…

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Cyclin-dependent kinase inhibitors (CDKIs) and endocrine therapy (ET) are the corner-stone of systemic therapy for patients with hormone-positive (HR+) HER2-negative metastatic breast cancer (MBC). However, limited data exist regarding rechallenge treatment strategies with CDKIs after limiting toxic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuentes-Antrás, Jesús, de Luna, Alicia, López de Sá, Alfonso, Ocaña, Alberto, García-Sáenz, José Ángel, Moreno, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581964/ https://www.ncbi.nlm.nih.gov/pubmed/33096323 http://dx.doi.org/10.1016/j.breast.2020.10.007

Ejemplares similares

The etiology of hypertransaminasemia in Turkish children
por: Serdaroglu, Filiz, et al.
Publicado: (2016)

From hypertransaminasemia to mucopolysaccharidosis IIIA
por: Krawiec, Paulina, et al.
Publicado: (2014)

Mild Hypertransaminasemia in Primary Care
por: Al-Busafi, Said A., et al.
Publicado: (2013)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Hypertransaminasemia and fatal lung disease: a case report
por: Santamaria, Francesca, et al.
Publicado: (2013)

Hypertransaminasemia and hypophosphoremia in an adolescent with anorexia nervosa: an event to watch for
por: Marchili, Maria Rosaria, et al.
Publicado: (2016)

Limited redundancy in genes regulated by Cyclin T2 and Cyclin T1
por: Ramakrishnan, Rajesh, et al.
Publicado: (2011)

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck
por: van Caloen, Gabrielle, et al.
Publicado: (2021)

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
por: de Luna Aguilar, Alicia Milagros, et al.
Publicado: (2023)

The Effects of Gluten-Free Diet on Hypertransaminasemia in Patients with Celiac Disease
por: Moghaddam, Mostafa Alavi, et al.
Publicado: (2013)

Incidental hypertransaminasemia in children—a stepwise approach in primary care
por: Costa, Joana Meneses, et al.
Publicado: (2023)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Characterization of the Synergistic Inhibition of I(K(erg)) and I(K(DR)) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor
por: Liu, Pin-Yen, et al.
Publicado: (2020)

Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2018)

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
por: Kim, Sunkyu, et al.
Publicado: (2020)

The effect of Helicobacter pylori eradication on liver enzymes in patients referring with unexplained hypertransaminasemia
por: Salehi, Hassan, et al.
Publicado: (2014)

Hypertransaminasemia in the course of infection with SARS-CoV-2: Incidence and pathogenetic hypothesis
por: Zippi, Maddalena, et al.
Publicado: (2020)

Early Hypertransaminasemia after Kidney Transplantation: Significance and Evolution According to Donor Type
por: Solà-Porta, Eulàlia, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
por: Strnad, M., et al.
Publicado: (2001)

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
por: Strnad, M., et al.
Publicado: (2001)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

c.761C>T Mutation Linked Hyper IgM Syndrome Presenting with Hypertransaminasemia and Arthritis
por: Celiksoy, Mehmet Halil, et al.
Publicado: (2014)

Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Villani, Rosanna, et al.
Publicado: (2019)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Beneficial effect of ursodeoxycholic acid in patients with acyl‐CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
por: Alonso‐Peña, Marta, et al.
Publicado: (2022)

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck
por: Seront, Emmanuel, et al.
Publicado: (2019)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series
por: Béchard, Laurent, et al.
Publicado: (2021)

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2023)

PReS-FINAL-1005: Hypertransaminasemia in systemic juvenile idiopathic arthritis during anti-interleukin 1 treatment
por: Gonzalez Fernandez, MI, et al.
Publicado: (2013)

Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge
por: Alicke, Bruno, et al.
Publicado: (2020)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Fatty liver disease and hypertransaminasemia hiding the association of clinically silent Duchenne muscular dystrophy and hereditary fructose intolerance
por: Paolella, Giulia, et al.
Publicado: (2012)

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
por: Bellet, Meritxell, et al.
Publicado: (2019)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis
por: Saleh, Ramy R., et al.
Publicado: (2019)

Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
por: Nagyiványi, Krisztián, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_da4m9papm9msk1jo8k2u5uhsgf